Mr. Aina Andrew meets with the Hon. Commissioner for Health, Lagos State.

The meeting was held at the sidelines of the FG initiative on stimulating local manufacturing of

Next-Gen Vaccine Platform Boosts Global Readiness

Area: Infectious Diseases Focus: mRNA & Recombinant Manufacturing Year: 2025

A modular vaccine platform combining mRNA and recombinant protein technologies is accelerating candidate design, scale-up, and regulatory readiness. The approach reduces time-to-clinic while improving consistency across antigen formats and adjuvant pairings.

Platform Architecture

Antigen design pipeline: bioinformatic epitope prediction and rapid construct iteration.
mRNA chassis: optimized UTRs and cap chemistry for durable expression.
LNP delivery: tunable particle characteristics for targeted biodistribution.
Recombinant protein lines: CHO and yeast systems for parallel evaluation.
Fill-finish orchestration: standardized aseptic workflows for quick lot release.

Regulatory and Quality Alignment

Documentation templates map to FDA, EMA, and WHO PQ expectations, ensuring early clarity on CMC, stability, and comparability. Digital batch records enable faster audits and traceability across sites.

Case Snapshot

An emergent paramyxovirus candidate progressed from sequence to GLP tox in under 16 weeks, supported by concurrent mRNA and protein prototyping. Early neutralization data informed dose selection and adjuvant choice.

At a glance: Dual-modality pipeline, harmonized QC, and global tech transfer packs to shorten critical-path timelines.

“Speed without quality trade-offs is achievable when design, analytics, and manufacturing share a single data backbone.”

What’s Next

Expansion into thermostable formulations and needle-free delivery will further improve deployment in low-resource settings. Industry partnerships are focused on distributed manufacturing to increase surge capacity.